Glioblastoma multiforme (GBM) is the most common form of primary brain cancer diagnosed in adults and expected to affect more than 12,000 individuals in the U.S. this year alone, according to the American Brain Tumor Association.
An estimated 30 to 40 percent of cancer patients treated with chemotherapy experience pain, according to the National Cancer Institute. Known as chemotherapy-induced peripheral neuropathy (CIPN), CIPN can produce sharp pains, numbness, tingling and or burning sensations in the hands and feet of cancer patients because of nerve damage caused by chemotherapy. However, a recent clinical trial utilizing a device first tested at VCU Massey Cancer Center provides further evidence that it can significantly reduce CIPN symptoms without the use of drugs or invasive treatments.
VCU Massey Cancer Center has made a significant investment in improving the region’s cancer care by becoming the only cancer care provider in Richmond to utilize the TrueBeam™ linear accelerator. This advanced machine incorporates the latest image-guided radiation therapy technologies and higher dose rates to more accurately target patients’ tumors while sparing healthy tissue, reducing side effects and decreasing treatment times. The advanced capabilities of the TrueBeam™ system allow physicians to better treat complex cancers such as lung, liver, prostate and head and neck tumors that are close to vital organs and delicate tissue.
New technology from ApoCell, Inc. that can detect liver cancer cells circulating in a patient’s bloodstream may remove the need for potentially dangerous liver biopsies, be used as a screening tool and, ultimately, speed up drug development, according to a pilot study presented this week by Virginia Commonwealth University (VCU) Massey Cancer Center researcher Andrew Poklepovic, M.D., at the AACR Annual Meeting 2012 in Chicago, IL.